Quadrant Capital Group LLC Cuts Position in Zoetis Inc. (NYSE:ZTS)

Quadrant Capital Group LLC reduced its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,923 shares of the company’s stock after selling 80 shares during the quarter. Quadrant Capital Group LLC’s holdings in Zoetis were worth $965,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ZTS. Mission Wealth Management LP raised its holdings in shares of Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares during the period. VeraBank N.A. grew its holdings in Zoetis by 4.1% during the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock valued at $254,000 after purchasing an additional 62 shares in the last quarter. HUB Investment Partners LLC increased its stake in Zoetis by 4.7% during the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock worth $224,000 after buying an additional 62 shares during the period. Procyon Advisors LLC lifted its holdings in Zoetis by 1.4% in the 4th quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators boosted its position in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after buying an additional 65 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling

In other news, Director Willie M. Reed sold 1,210 shares of the company’s stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the transaction, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 in the last three months. 0.16% of the stock is owned by insiders.

Zoetis Stock Performance

Zoetis stock opened at $151.76 on Monday. The company has a market cap of $67.96 billion, a PE ratio of 27.74, a P/E/G ratio of 2.78 and a beta of 0.92. Zoetis Inc. has a 12 month low of $144.69 and a 12 month high of $200.33. The company has a fifty day moving average price of $165.71 and a two-hundred day moving average price of $173.26. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.32%. Zoetis’s dividend payout ratio is currently 36.56%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on ZTS shares. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley dropped their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Piper Sandler raised their price target on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. Finally, UBS Group initiated coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $215.90.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.